Similar articles

• Effect of intravenous 1-alpha-hydroxyvitamin D3 on secondary hyperparathyroidism in chronic uremic patients on maintenance hemodialysis.

  Brandi L, Daugaard H, Tvedegaard E, Storm T, Olgaard K. Brandi L, et al. Nephron. 1989;53(3):194-200. doi: 10.1159/000185744. Nephron. 1989. PMID: 2797340
• Value of 1-alpha-hydroxy vitamin D3 in treatment of primary hyperparathyroidism before parathyroidectomy.

  Heath DA, Van't Hoff W, Barnes AD, Gray JG. Heath DA, et al. Br Med J. 1979 Feb 17;1(6161):450-2. doi: 10.1136/bmj.1.6161.450. Br Med J. 1979. PMID: 427402 Free PMC article.
• [Evaluation of the treatment efficacy of secondary hyperparathyroidism with oral pulse doses of alphacalcidol].

  Switalski M, Kuriga M, Wańkowicz Z. Switalski M, et al. Pol Arch Med Wewn. 1997 Oct;98(10):358-65. Pol Arch Med Wewn. 1997. PMID: 9557090 Clinical Trial. Polish.
• Hypoparathyroidism: practice and theoretical backgrounds for 1 alpha(OH)D3 treatment.

  Ogata E. Ogata E. Bone Miner. 1990 Jun;9(3):229-32. doi: 10.1016/0169-6009(90)90040-m. Bone Miner. 1990. PMID: 2364181 No abstract available.
• 1-alpha-Hydroxyvitamin D3 derivatives in the treatment of renal bone diseases: justification and optimal modalities of administration.

  Fournier A, Morinière PH, Oprisiu R, Yverneau-Hardy P, Westeel PF, Mazouz H, el Esper N, Ghazali A, Boudailliez B. Fournier A, et al. Nephron. 1995;71(3):254-83. doi: 10.1159/000188732. Nephron. 1995. PMID: 8569975 Review.